PROM1 and vulva cancer: Applying the defined cut-off values for 40 patients with vulvar cancer, in the group of patients with numbers of CD133+ CTCs < 14/ml (light blue line, Fig. 5A), numbers of CD49f+ CD133+ CTCs < 5/ml (light red line, Fig. 5B) or numbers of PD-L1+ CD49f+ CD133+ CTCs < 5/ml (light purple line, Fig. 5C) after therapy, 6.5-year RFS rate was 68.8%, 90% or 100%, respectively.